BACKGROUND AND PURPOSE: Considerable evidence indicates that the beta(2)-adrenoceptor agonist clenbuterol decreases apoptosis in a rodent model of ischaemic cardiomyopathy. In this study, we investigated the effects of clenbuterol on infarct size caused by myocardial ischaemia/reperfusion (I/R) in anaesthetized rats. EXPERIMENTAL APPROACH: Rats were randomly assigned to the following groups: (i) sham (ii) I/R (iii) clenbuterol + I/R (iv) ICI 118551 + clenbuterol + I/R (v) metoprolol + clenbuterol + I/R (vi) metoprolol + I/R (vii) pertussis toxin + clenbuterol + I/R. Under anaesthesia, left anterior descending coronary artery was occluded for 30 min followed by reperfusion for 2 h. KEY RESULTS: Compared with the control I/R group,the clenbuterol (0.5 mg.kg(-1), i.p.) group had reduced infarct size, improved diastolic function and sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase (SERCA) activity, increased superoxide dismutase activity, and decreased malondialdehyde (MDA) level and LDH, CK release. Clenbuterol increased the phosphorylation of ERK1/2, which resulted in inhibition of myocardial apoptosis as indicated by the reduction of terminal deoxynucleotidyltransferase end labelling-positive staining, Bax/Bcl-2 mRNA and caspase-3 protein expression. The G(i)-protein inhibitor pertussis toxin blocked the clenbuterol-induced improvement in cardiac function and infarct size. Pretreatment with ICI 118551(a selective beta(2)-adrenoceptor antagonist) inhibited the effects of clenbuterol mentioned above. The beta(1)-adrenoceptor agonist metoprolol had similar effects to clenbuterol but failed to reduce MDA and improve SERCA activity. When administered together, metoprolol and clenbuterol did not induce synergistic effects. CONCLUSIONS AND IMPLICATIONS: Clenbuterol pretreatment provides significant cardioprotection against ischaemia/reperfusion injury and this is mediated by the beta(2)-adrenoceptor-G(i)-protein signalling. A combination of the beta(2)-adrenoceptor agonist clenbuterol and the beta(1)-antagonist metoprolol did not lead to a synergistic anti-apoptotic effect.
BACKGROUND AND PURPOSE: Considerable evidence indicates that the beta(2)-adrenoceptor agonist clenbuterol decreases apoptosis in a rodent model of ischaemic cardiomyopathy. In this study, we investigated the effects of clenbuterol on infarct size caused by myocardial ischaemia/reperfusion (I/R) in anaesthetized rats. EXPERIMENTAL APPROACH: Rats were randomly assigned to the following groups: (i) sham (ii) I/R (iii) clenbuterol + I/R (iv) ICI 118551 + clenbuterol + I/R (v) metoprolol + clenbuterol + I/R (vi) metoprolol + I/R (vii) pertussis toxin + clenbuterol + I/R. Under anaesthesia, left anterior descending coronary artery was occluded for 30 min followed by reperfusion for 2 h. KEY RESULTS: Compared with the control I/R group,the clenbuterol (0.5 mg.kg(-1), i.p.) group had reduced infarct size, improved diastolic function and sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase (SERCA) activity, increased superoxide dismutase activity, and decreased malondialdehyde (MDA) level and LDH, CK release. Clenbuterol increased the phosphorylation of ERK1/2, which resulted in inhibition of myocardial apoptosis as indicated by the reduction of terminal deoxynucleotidyltransferase end labelling-positive staining, Bax/Bcl-2 mRNA and caspase-3 protein expression. The G(i)-protein inhibitor pertussis toxin blocked the clenbuterol-induced improvement in cardiac function and infarct size. Pretreatment with ICI 118551(a selective beta(2)-adrenoceptor antagonist) inhibited the effects of clenbuterol mentioned above. The beta(1)-adrenoceptor agonist metoprolol had similar effects to clenbuterol but failed to reduce MDA and improve SERCA activity. When administered together, metoprolol and clenbuterol did not induce synergistic effects. CONCLUSIONS AND IMPLICATIONS: Clenbuterol pretreatment provides significant cardioprotection against ischaemia/reperfusion injury and this is mediated by the beta(2)-adrenoceptor-G(i)-protein signalling. A combination of the beta(2)-adrenoceptor agonist clenbuterol and the beta(1)-antagonist metoprolol did not lead to a synergistic anti-apoptotic effect.
Authors: T M Scarabelli; R A Knight; N B Rayment; T J Cooper; A Stephanou; B K Brar; K M Lawrence; G Santilli; D S Latchman; G F Baxter; D M Yellon Journal: J Immunol Methods Date: 1999-08-31 Impact factor: 2.303
Authors: Oliver J Sichelschmidt; Claudia Hahnefeld; Thomas Hohlfeld; Friedrich W Herberg; Karsten Schrör Journal: Cardiovasc Res Date: 2003-06-01 Impact factor: 10.787
Authors: Laurel A Grisanti; Anna M Gumpert; Christopher J Traynham; Joshua E Gorsky; Ashley A Repas; Erhe Gao; Rhonda L Carter; Daohai Yu; John W Calvert; Andrés Pun García; Borja Ibáñez; Joseph E Rabinowitz; Walter J Koch; Douglas G Tilley Journal: Circulation Date: 2016-06-30 Impact factor: 29.690
Authors: Xingxu Wang; Li Ni; Lei Yang; Quanlu Duan; Chen Chen; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang Journal: Mol Pharmacol Date: 2013-10-21 Impact factor: 4.436
Authors: Louise E See Hoe; Jan M Schilling; Anna R Busija; Kristofer J Haushalter; Victoria Ozberk; Malik M Keshwani; David M Roth; Eugene Du Toit; John P Headrick; Hemal H Patel; Jason N Peart Journal: Eur J Pharmacol Date: 2016-06-30 Impact factor: 4.432
Authors: Alexander R Lyon; Sian E Harding; Helen Paur; Peter T Wright; Markus B Sikkel; Matthew H Tranter; Catherine Mansfield; Peter O'Gara; Daniel J Stuckey; Viacheslav O Nikolaev; Ivan Diakonov; Laura Pannell; Haibin Gong; Hong Sun; Nicholas S Peters; Mario Petrou; Zhaolun Zheng; Julia Gorelik Journal: Circulation Date: 2012-06-25 Impact factor: 29.690